Indication: Hematological Malignancies
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Astex Pharmaceuticals
Email for more information: Heme-NCIResearch@nortonhealthcare.org
